Current Treatment Options in Oncology

, Volume 15, Issue 2, pp 281–301

Managing The Skin Toxicities From New Melanoma Drugs

Skin Cancer (WH Sharfman, Section Editor)

DOI: 10.1007/s11864-014-0284-6

Cite this article as:
Mavropoulos, J.C. & Wang, T.S. Curr. Treat. Options in Oncol. (2014) 15: 281. doi:10.1007/s11864-014-0284-6

Opinion Statement

Patients treated with ipilimumab or targeted inhibitors of the RAF-MEK-ERK pathway (vemurafenib, dabrafenib, and trametinib) for advanced cutaneous melanoma often experience drug-related skin toxicities denoted as dermatologic adverse events (DAEs). Although rarely life-threatening, DAEs may emerge dramatically and potentially compromise oncologic therapy if not managed in a timely and effective manner. Early recognition of DAEs is critical to providing optimal skin care and prompt consultation with a dermatologist should be obtained when a diagnosis is unclear. The expanding utilization of new melanoma drugs compels physicians to maintain a watchful eye for both known and novel DAEs and to adopt a low threshold to biopsy worrisome skin findings. Numerous therapeutic options are available to manage DAEs including topical and systemic agents as well as surgical and destructive modalities. Applying such methods improves overall patient care and optimizes the effectiveness of new therapies for advanced cutaneous melanoma.

Keywords

IpilimumabVemurafenibDabrafenibTrametinibSkin toxicitiesMelanoma

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Dermatology, Johns Hopkins Outpatient CenterJohns Hopkins UniversityBaltimoreUSA